



Durham Region Health Department FAX about...

For Health Care Professionals



CAMH Continuing Education- Methadone & Buprenorphine

The Centre for Addictions and Mental Health (CAMH) is offering two continuing education sessions on Methadone and Buprenorphine for family physicians and nurse practitioners.

Methadone and Buprenorphine are first-line treatments for opioid use disorder and its use is associated with reduced morbidity, mortality, blood-borne viral infections, and social harms. Comprehensive primary care includes both prescribing and supporting integrated opioid agonist therapy.

Webinar: Caring for persons on methadone in primary care: Toward safer, more inclusive care.

The purpose of this free webinar is to help primary care providers feel comfortable providing comprehensive care to patients prescribed methadone.

You will learn:

- The evidence supporting methadone treatment for opioid use disorder.
- Important drug-drug interactions, acute pain management for people receiving methadone, common side effects and implications of missed doses or treatment interruptions.
- Harm reduction strategies for people who use opioids, and
- Communication pearls for collaboration among pharmacists, primary care providers and specialist colleagues.

Date: November 14, 2023

Time: 12:00-1:00 pm (EST)

For more information and to register visit: <https://kmb.camh.ca/eenet/events/webinar-caring-for-persons-on-methadone-in-primary-care-toward-safer-more-inclusive-care>

... over

905-668-2020 or 1-800-841-2729 | durham.ca/health

If you require this information in an accessible format, contact 1-800-841-2729.



On Demand (eLearning): Buprenorphine Treatment for Opioid Use Disorder

This course aims to present a framework for providing maintenance treatment for opioid use disorder with buprenorphine, including its use in a primary care setting. The course walks the learner through the key elements of selecting, preparing, initiating, and maintaining a patient with opioid use disorder on buprenorphine treatment.

Learning Objectives:

- Outline the evidence supporting buprenorphine as a first line opioid agonist, for opioid use disorder treatment.
- Prior to beginning their treatment, diagnose patients for opioid use disorder based on the DSM-5 criteria.
- Prior to beginning their treatment, assess patients for concurrent conditions that may be affecting treatment with buprenorphine.
- Determine the best evidence- based treatment course for the patient's context and values.
- Achieve safe and effective patient induction onto buprenorphine in an ambulatory setting.
- Manage opioid overdoses in the ambulatory setting, and
- Manage the maintenance stage of buprenorphine treatment in the ambulatory setting with safe, "client-centred care."

Open from: September 11, 2023, to August 30, 2024.

Registration Closes: July 26, 2024.

Cost: \$425.00

This course is accredited for:

- The College of Family Physicians of Canada - 13.5 Mainpro+ credits
- The Royal College of Physicians and Surgeons - 13.5 Section 1 hours

For more information and to register visit: <https://www.camh.ca/en/education/continuing-education-programs-and-courses/continuing-education-directory/buprenorphine-treatment-for-opioid-use-disorder>

If you have any feedback about Fax Abouts or want to recommend a topic for distribution, please email Faxabout@durham.ca.

October 23, 2023

905-668-2020 or 1-800-841-2729 | durham.ca/health

If you require this information in an accessible format, contact 1-800-841-2729.

